Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α2-adrenoceptor-catecholamine production axis in heart failure

British Journal of Pharmacology

Volumn 166, Issue 8, 2012, Pages 2430-2440

  Rengo, G ^a,b,c   Lymperopoulos, A ^d   Zincarelli, C ^a,b,c   Femminella, G D ^c   Liccardo, D ^c   Pagano, G ^c   De Lucia, C ^c   Cannavo, A ^c   Gargiulo, P ^c   Ferrara, N ^a,e   Perrone Filardi, P ^c   Koch, W J ^b   Leosco, D ^c  

^a IRCCS   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MOLISE   (Italy)

Author keywords

blocker; adrenal GRK2; catecholamines; heart failure; sympathetic overactivity

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR KINASE 2;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE SYNTHESIS; CHROMAFFIN CELL; CONTROLLED STUDY; DRUG DOSE INCREASE; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENAL GLANDS; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BISOPROLOL; CATECHOLAMINES; CELLS, CULTURED; CHROMAFFIN CELLS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART FAILURE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 84864444752     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01972.x     Document Type: Article

References (47)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Al-Hesayen A, Azevedo ER, Floras JS, Hollingshead S, Lopaschuk GD, Parker JD, (2005). Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 7: 618-623. (Pubitemid 40732995)
3. Andersson B, Hamm C, Persson S, Wikström G, Sinagra G, Hjalmarson A, et al,. (1994). Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 23: 1397-1404. (Pubitemid 24158009)
4. Blanchet M, Ducharme A, Racine N, Rouleau JL, Tardif JC, Juneau M, et al,. (2003). Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). Am J Cardiol 92: 548-553. (Pubitemid 37013407)
5. Bristow MR, (2000a). Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail 6: 8-14. (Pubitemid 30439433)
6. Bristow MR, (2000b). β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569. (Pubitemid 30080872)
7. Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ, (2002). Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol 61: 749-758. (Pubitemid 34273154)
8. Feldman DS, Carnes CA, Abraham WT, Bristow MR, (2005). Mechanisms of disease: β-adrenergic receptors in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2: 475-483. (Pubitemid 41223525)
9. Foody JM, Farrell MH, Krumholz HM, (2002). beta-Blocker therapy in heart failure: scientific review. JAMA 287: 883-889. (Pubitemid 34252037)
10. Foucart S, Nadeau R, de Champlain J, (1988). Local modulation of adrenal catecholamines release by beta-2 adrenoceptors in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol 337: 29-34. (Pubitemid 18061411)
11. Foucart S, de Champlain J, Nadeau R, (1991). Modulation by beta-adrenoceptors and angiotensin II receptors of splanchnic nerve evoked catecholamine release from the adrenal medulla. Can J Physiol Pharmacol 69: 1-7.
12. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al,. (1996). Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817-2825. (Pubitemid 26411746)
13. Goldsmith SR, (2004). Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 1: 45-50.
14. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al,. (2009). 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol 53: e1-e90.
15. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, et al,. (2005). Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 26: 1752-1758. (Pubitemid 41219848)
16. Lamba S, Abraham WT, (2000). Alterations in adrenergic receptor signaling in heart failure. Heart Fail Rev 5: 7-16. (Pubitemid 30301507)
17. Lee CS, Tkacs NC, (2008). Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 19: 364-385.
18. Leosco D, Rengo G, Iaccarino G, Filippelli A, Lymperopoulos A, Zincarelli C, et al,. (2007). Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am J Physiol Heart Circ Physiol 293: H1596-H1603. (Pubitemid 47367205)
19. Leosco D, Rengo G, Iaccarino G, Golino L, Marchese M, Fortunato F, et al,. (2008). Exercise promotes angiogenesis and improves beta-adrenergic receptor signaling in the post-ischaemic failing rat heart. Cardiovasc Res 78: 385-394. (Pubitemid 351556096)
20. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, et al,. (2002). Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346: 1357-1365. (Pubitemid 34754608)
21. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ, (2007a). Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 13: 315-323. (Pubitemid 46376685)
22. Lymperopoulos A, Rengo G, Koch WJ, (2007b). Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med 13: 503-511. (Pubitemid 350123195)
23. Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ, (2008). Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther 16: 302-307. (Pubitemid 351168039)
24. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ, (2009). An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA 106: 5825-5830.
25. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW 2nd, Koch WJ, (2010). Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem 285: 16378-16386.
26. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ, (2011). Adrenal β-arrestin-1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 57: 356-365.
27. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Nemanich JW, Veith RC, Abrass IB, Stratton JR, (1990). Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 66: 843-848. (Pubitemid 20352265)
29. Petrofski JP, Koch WJ, (2003). The β-adrenergic receptor kinase (βARK1) in heart failure. J Mol Cell Cardiol 35: 1167-1174. (Pubitemid 37163522)
30. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, et al,. (2007). Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115: 2506-2515. (Pubitemid 46763224)
31. Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, et al,. (2008). G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 103: 413-422.
32. Rengo F, Leosco D, Iacovoni A, Rengo G, Golino L, Borgia F, et al,. (2004). Epidemiology and risks factor for heart failure in the elderly. Ital Heart J 5 (Suppl. 9): 3S-10S.
33. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, et al,. (2009). Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119: 89-98.
34. Rengo G, Leosco D, Zincarelli C, Marchese M, Corbi G, Liccardo D, et al,. (2010). Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol 298: H2032-H2038.
35. Rengo G, Lymperopoulos A, Leosco D, Koch WJ, (2011). GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 50: 785-792.
36. Sabbah HN, (2004). Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 9: 91-97. (Pubitemid 39485470)
37. Santostasi G, Fraccarollo D, Dorigo P, Egloff C, Miraglia G, Marinato PG, et al,. (1998). Early reduction in plasma norepinephrine during beta-blocking therapy with metoprolol in chronic heart failure. J Card Fail 4: 177-184. (Pubitemid 28433920)
38. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M, (2000). The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. J Am Coll Cardiol 35: 398-404. (Pubitemid 30125531)
39. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, et al,. (2002). Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105: 1797-1803. (Pubitemid 34408889)
40. Tevaearai HT, Koch WJ, (2004). Molecular restoration of beta-adrenergic receptor signaling improves contractile function of failing hearts. Trends Cardiovasc Med 14: 252-256. (Pubitemid 39297024)
41. The RESOLVD Investigators (2000). Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Circulation 101: 378-384.
42. Tilley DG, Rockman HA, (2006). Role of β-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Exp Rev Cardiovasc Ther 4: 417-432. (Pubitemid 43803144)
43. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J, (2009). The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54: 1747-1762.
44. Watanabe K, Ohta Y, Inoue M, Ma M, Wahed MI, Nakazawa M, et al,. (2001). Bisoprolol improves survival in rats with heart failure. J Cardiovasc Pharmacol 38: S55-S58. (Pubitemid 33104684)
45. Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akaishi M, et al,. (1996). Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Am Heart J 131: 329-336. (Pubitemid 26043394)
46. 2Adrenergic Receptor Gi Signaling in the Heart. The Good, the Bad, and the Ugly. Circ Res 97: 507-509. (Pubitemid 41361739)
47. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE, (2010). Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 3: 81-89.